• On sale!


  • Visufarma S.p.A.
  • 024851026

Indicated in case of allergy, ocular itch and red eyes.

Indicated in case of allergic conjunctivitis.

Deductible over-the-counter drug.

Antihistamine action.

info_outline View product sheet
Final Price €20.90
check_circle Available
Shipped within 24 h
  Convenient and safe payments

Even with a credit card

  Shipping in 24h all over the world

Fast and safe international shipping worldwide

  Fast returns

14 days to reconsider

  Pharmaceutical experience

Always at your service. Experts in international shipping

Other products Others products at unbeatable price

Visufarma S.p.A.

Discover all products


Therapeutic indications

Treatment of toxic, allergic and spring conjunctivitis, with subacute and chronic progression.

Dosage and method of use

1-2 drops in the conjunctival fornix four times a day. Before use, make sure that the single-dose container is intact. Visuglican in single-dose container should only be used immediately after opening. Any residue must not be used. Avoid letting the tip of the container come into contact with your eye or any other surface.


Hypersensitivity to the active substances or to any of the excipients listed in paragraph 6.1.

Side effects

Irritation and burning phenomena have rarely been reported. In these cases it is advisable to suspend treatment. (see section 4.3) Very rarely, cases of corneal calcification have been reported associated with the use of phosphate-containing eye drops in patients with significantly damaged cornea. Reporting of suspected adverse reactions. Reporting suspected adverse reactions that occur after authorization of the medicinal product is important, as it allows continuous monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system at: https://www.aifa.gov.it/web/guest/content/segnalazioni-reazioni-avverse.

Special warnings

To be used under the direct supervision of a doctor. Do not use if the solution is not clear. Visuglican 10 ml bottle contains disodium phosphate 6.50 mg per 1 ml equivalent to 65 mg/10 ml, and monosodium phosphate 2 mg per 1 ml equivalent to 20 mg/10 ml. Visuglican single-dose contains disodium phosphate 8.12 mg per 1 ml equivalent to 4.06 mg/0.5 ml and monosodium phosphate 4.5 mg per 1 ml equivalent to 2.25 mg/0.5 ml.

Pregnancy and breastfeeding

As with any drug it is advisable, when possible, to avoid administration during the first trimester of pregnancy. If the use of this product is considered essential in a nursing mother, the patient should discontinue breast-feeding.

Expiration and conservation

Bottle: Store at a temperature not exceeding 25°C. Single dose: keep the product away from heat sources.

Interactions with other drugs

There are no known interactions with other drugs. However, additive effects are possible when Visuglican is administered simultaneously with H 2 antagonists (cimetidine) and corticosteroids.


No overdose phenomena have been reported.

Active principles

100 ml of eye drops, solution contain: Active ingredients: Sodium Cromoglycate 4 g; Chlorphenamine maleate 0.2 g. For the full list of excipients, see section 6.1


Visuglican Eye Drops, solution in 10 ml bottle: 100 ml of eye drops contain: Sodium edetate; Disodium phosphate; Monosodium phosphate; Purified water. Visuglican Eye Drops, solution in single-dose containers: 100 ml of eye drops contain: Sodium edetate; Disodium phosphate; Monosodium phosphate; Water for injections.


Data sheet

40 mg / ml + 2 mg / ml eye drops solution 25 single-dose containers of 0.5 ml
Product Type
ATC code
ATC description
Chromoglycic acid, associations
Therapeutic Group
Active principle
sodium cromoglycate + chlorphenamine maleate
Pharmaceutical form
eye drops
Type of Administration
pipette / single-dose containers
25 vial / vial / vial
0.5 milliliters
Quantity of the Active Ingredient
4G (sodium cromoglycate) +, 2G (chlorphenamine maleate)
Recipe required
SOP - non-prescription medicine
chat Comments (0)